Kamada Collaborates With Baxalta On Phase 1/2 Trial Of Alpha-1 Antitrypsin

(RTTNews) - Kamada Ltd. (KMDA) announced it has entered into a collaboration with Baxalta International, a subsidiary of Baxter International Inc. (BAX), on a Phase 1/2 clinical trial of Kamada's alpha-1 antitrypsin treatment for the prevention of lung transplant rejection. Baxalta will collaborate in the development and funding of the study, which will be conducted in Israel.

Baxalta has distribution rights to intravenous alpha-1 antitrypsin for all indications in the U.S., Canada, Australia and New Zealand, while Kamada has rights in all other territories and all other formulations.